ReviewEFORT open reviews2024
Bacteriophage therapy in musculoskeletal infections: from basic science to clinical application.
Review in EFORT open reviews, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bacteriophage therapy as an innovative strategy for the treatment of Periprosthetic Joint Infection: a systematic review.International orthopaedics · 2024Pooled it
- Antibiotic-Free Strategies for Managing Antimicrobial-Resistant Infections.Pharmaceutics · 2026Review
- Bacteriophage Therapy for Breast Implants: A Translational Perspective and Future Directions.Plastic and reconstructive surgery. Global open · 2026Article
- [Bacteriophage Therapy in Orthopaedics and Trauma].Acta chirurgiae orthopaedicae et traumatologiae Cechoslovaca · 2026Review
- Periprosthetic Joint Infection: Biofilm Pathogenesis, Immune Dysregulation, and Emerging Prosthetic Interface Strategies.Biology · 2026Review
- 3D Printing of Bacteriophage-Loaded Hydrogels: Development of a Local and Long-Lasting Delivery System.Advanced healthcare materials · 2026Article
- Phage therapy in revision arthroplasty: State of the art and application protocols.Arthroplasty (London, England) · 2026Review
- Fracture-Related Infections: Current Status and Perspectives from the International Society of Antimicrobial Chemotherapy.Antibiotics (Basel, Switzerland) · 2025Review
- Editorial: Bacteriophage therapy in orthopedics-Key questions and emerging answers.Journal of orthopaedics and traumatology : official journal of the Italian Society of Orthopaedics and Traumatology · 2025Article
- [Recent advances regarding diagnosis and treatment of fracture-related infection].Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery · 2025Review
- Antimicrobial resistance in orthopedics: microbial insights, clinical impact, and the necessity of a multidisciplinary approach-a review.Acta orthopaedica · 2025Review
- Current Applications and the Future of Phage Therapy for Periprosthetic Joint Infections.Antibiotics (Basel, Switzerland) · 2025Review
- A Longer Duration of Intravenous Antibiotic Treatment for Patients with Early Periprosthetic Joint Infections Is Not Associated with a Lower Failure Rate.Antibiotics (Basel, Switzerland) · 2025Article
- Debridement, antimicrobial therapy, and implant retention (DAIR) as curative strategy for acute periprosthetic hip and knee infections: a position paper of the European Bone & Joint Infection Society (EBJIS).Journal of bone and joint infection · 2025Article
- Prevention and Modern Strategies for Managing Methicillin-Resistant Staphylococcal Infections in Prosthetic Joint Infections (PJIs).Antibiotics (Basel, Switzerland) · 2024Review
- Optimization of bacteriophage therapy for difficult-to-treat musculoskeletal infections: a bench-to-bedside perspective.Frontiers in cellular and infection microbiology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The treatment of musculoskeletal infections (MSIs), including periprosthetic joint infection (PJI) and fracture-related infection (FRI), is often complicated by biofilm-related challenges necessitating multiple revision surgeries and incurring substantial costs. The emergence of antimicrobial resistance (AMR) adds to the complexity of the problem, leading to increased morbidity and healthcare expenses. There is an urgent need for novel antibacterial strategies, with the World Health Organization endorsing non-traditional approaches like bacteriophage (phage) therapy. Phage therapy, involving the targeted application of lytic potent phages, shows promise in the treatment of MSIs. Although historical clinical trials and recent case studies present significant milestones in the evolution of phage therapy over the past century, challenges persist, including variability in study designs, administration protocols and phage selection. Efforts to enhance treatment efficacy consist of personalized phage therapy and combination with antibiotics. Future perspectives entail addressing regulatory barriers, standardizing treatment protocols, and conducting high-quality clinical trials to establish phage therapy's efficacy for the treatment of MSIs. Initiatives like the PHAGEFORCE study and the PHAGEinLYON Clinic programme aim to streamline phage therapy, facilitating personalized treatment approaches and systematic data collection to advance its clinical utility in these challenging infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.